title: Reply to the letter to the editor 'Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?' by Abali et al.
authors.affiliation: Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo. Electronic address: k-sugi.srg2@tmd.ac.jp.
authors.forename: K
authors.initials: K
authors.lastname: Sugihara
authors.affiliation: Cancer Chemotherapy Center, Osaka Medical College Hospital, Osaka.
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.affiliation: Department of Translational Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ishiguro
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*; D014498:Uracil / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; D002955:Leucovorin